Manufacturers have developed distinct strategies in an attempt to deal with these critical issues of long-term lead Background-Implantable cardioverter-defibrillator (ICD) therapy in children and congenital heart disease patients is hampered by poor long-term lead survival. Lead extraction is technically difficult and carries substantial morbidity. We sought to determine the outcomes of ICD leads in pediatric and congenital heart disease patients.
I mplantable cardioverter-defibrillator (ICD) therapy in children and congenital heart disease (CHD) patients may be a lifesaving treatment, but it is often hampered by poor longterm lead survival. Recent data on adult patients showed ICD lead survival of only 60% at 8 years after implantation, 1 with even worse lead performance previously reported in pediatric and CHD patients. 2 However, as the indications for ICD placement in pediatrics and CHD expand and with smaller devices being manufactured, the number of children and young adults with ICDs continues to increase. 3 Many of these patients will outlive the functionality of their implanted leads or outgrow the length of intracardiac leads, necessitating lead replacement, revision, or extraction. Transvenous lead extraction is technically challenging and carries a substantial risk of morbidity and mortality. 4 performance and easier extractability, including thinner and isodiametric lead bodies or an expanded polytetrafluoroethylene (ePTFE; Gore, Flagstaff, AZ) defibrillator coil coating. Both of these design changes were thought to improve the ease of lead removal but have not been evaluated in either children or CHD. A subset of the thin leads, Fidelis (Medtronic, Minneapolis, MN), eventually demonstrated a high rate of lead failure, resulting in their removal from the market in 2007. The purpose of the present study was to evaluate the failure rate and extractability of ICD leads in pediatric and congenital patients, with a focus on thin leads (≤7F outer diameter) and ePTFE-coated leads.
Methods
The Pediatric Lead Extractability and Survival Evaluation (PLEASE) study began as a phase IV international, multicenter, open-label prospective study (NCT00335036) facilitated by the Pediatric and Congenital Electrophysiology Society. Initially a randomized study to compare transvenous thin leads (Medtronic and St. Jude Medical, Sylmar, CA) with ePTFE-coated leads (Boston Scientific, Natick, MA), the study design changed to a parallel assignment registry when the Fidelis lead (one of the thin leads) had a clinical advisory as a result of a higher-than-expected incidence of failure, prompting concern about continued clinical equipoise. The overall proportion of patients enrolled before study design conversion was ≈20%. All consecutively implanted patients were enrolled from all participating centers during the study period in the registry.
Pediatric and CHD patients who underwent ICD lead implantation from January 2005 to June 2010 were eligible. The end date was chosen to coincide with the National Cardiovascular Data Registry ICD Registry version 2.1 release (which specifically includes pediatric patients, CHD data entry fields, and lead data). Specific patient demographic, lead implantation, failure, and extraction data were collected. Lead diameter, fixation mechanism (active versus passive), number of coils (single versus dual), and type of coil insulation were obtained on the basis of the reported manufacturer lead model. Leads were defined as thin when the outer diameter was ≤ 7F ( Table I in the  online-only Data Supplement) . Leads with specifically ePTFE-coated coils did not include leads with ethylene/tetrafluoroethylene copolymer-, PTFE-, or Optim-(silicone and PTFE polymer mix) coated coils ( Table I in the online-only Data Supplement). Lead extraction was defined as simple traction when no locking stylet or dissection sheath was used and as advanced extraction when a locking stylet with a dissection sheath was used. A total of 24 centers participated, and each site obtained local research ethics approval. Deidentified data were sent to the primary investigator center for verification, collation, and statistical analysis.
Statistical Analysis
The data are presented as patient-specific and lead-specific variables. Continuous variables were evaluated for the normality of their distribution, are presented as mean with standard deviation, and were analyzed with the 2-sample t test. Multiple samples with normal distribution of the residuals were analyzed with ANOVA. Multiple samples with nonnormal distribution of the residuals are presented as median with interquartile range (25th-75th percentile) and were analyzed with the Kruskal-Wallis test. Categorical variables are presented as counts with percentages and were analyzed with the Fisher exact or χ 2 test. Univariate analysis of lead data did not account for clustering of outcomes by patient. For nonfailed and nonextracted leads in patients with no reported date of death or cardiac transplantation, lead age was calculated using the study end date of June 30, 2010.
A Cox proportional hazard model was used to examine for independent predictors of lead failure. The model was stratified by clinical practice era (2005-2007 versus 2008-2010) related to a recalled lead. For patients with >1 implanted lead during the study period, only the first lead failure was analyzed in the model. Lead failure did not include extracted leads with no reported failure. Multivariable logistic regression was used to examine for predictors of the need for advanced techniques in patients having undergone lead extraction. The logistic regression model was fit by use of the generalized estimating equation with an exchangeable correlation structure to account for clustering of outcomes by patient. Score test P values are reported for the multivariable generalized estimating equation model. All models were built with the use of variables that were of clinical relevance and significantly differently distributed between the 2 groups (P≤0.1) on univariate analysis or selected a priori. All variables included in the models are listed in the associated tables.
Kaplan-Meier survival curves were constructed to examine the time-dependent probability of lead survival. Adjusted P values were used for multiple comparisons. To avoid informative censoring, extracted leads with no reported failure and leads removed at the time of death or cardiac transplantation were reviewed. If there was no clear evidence of impending lead failure before extraction, the corresponding lead age was censored. Two-tailed values of P<0.05 were considered statistically significant. Statistical analysis was performed with SAS 9.3 (SAS Institute Inc, Cary, NC).
Results
A total of 878 patients and 965 leads were included in this study. Data were collected from 24 international centers. The number of leads implanted during the 5.5-year study period ranged from 45 to 199 in the 10 higher-volume centers and from 2 to 38 in the 14 lower-volume centers. The proportion of leads implanted per calendar year, over the study period, and by age group is shown in Figure 1A and 1B. Patient-and lead-specific variables are presented in Table 1 . The mean patient age at implantation was 18.6 years (range, 0.1-62.7 years), with 150 patients (17%) being <12 years of age. The mean follow-up was 2.6 years (range, 0.1-5.5 years). The majority of implanted ICD systems (59%) were dual chamber ( Table 1) . At the end of the study, 10 patients were reported to have died and 28 underwent cardiac transplantation. Reports on the cause of death were available for 7 patients. Two deaths were associated with failed appropriate shocks, and both patients had an azygos vein ICD coil placed as a result of failed initial defibrillation testing at the time of implantation. Details on subsequent defibrillation testing and safety margin ICD shock programming were not available. The remaining 5 deaths were associated with the following: refractory ventricular arrhythmia, pulseless electric activity after successful defibrillation, end-stage ventricular dysfunction, a massive stroke after left ventricular outflow tract resection, and a noncardiac cause.
The mean lead age was 2.3 years (range, 0.1-5.7 years), and the majority of the implanted leads were thin (54%) with an outer diameter of ≤7F (Table 1) . Of the 525 thin leads, 300 (57%) were Sprint Fidelis leads, 263 (50%) were single coil, and 495 (94.0%) had an active fixation mechanism. Of the 440 nonthin leads, 223 (51%) were ePTFE coated, 210 (48%) were single coil, and 384 (87%) had an active fixation mechanism. Overall, 14% of leads failed in 15% of patients.
(thin leads in 110 of 150). A higher proportion of dualchamber systems were in the failed leads group, but when all 3 groups-single-chamber, dual-chamber, and biventricular systems-were compared, the difference was not statistically significant ( Table 1) .
A comparison of lead characteristics (Table 1) showed that lead failure was more likely to occur at a younger lead age and more frequently in thin leads, specifically Fidelis leads. Single coil was slightly more prevalent among the failed leads (57% versus 48%) but was not statistically significant. Leads with ePTFE (exclusively >7F outer diameter) were less likely to fail. Low-volume centers (≤40 implantations over the 5.5-year study period) did not have a higher incidence of lead failure than centers with >40 implantations over the study period.
In light of the high failure rate of Fidelis leads and the recent advisory on Riata and Riata ST leads (St. Jude Medical), with a distinctive inside-out type of abrasion, the 2 lead groups were compared along with all the other leads in the study. Riata ST Optim leads were not included in the Riata/Riata ST group. Failure for the Riata/Riata ST leads was defined as electric failure, and considering this study period, fluoroscopic or chest x-ray methodical screening for structural lead abnormalities was not considered. The differences in patient and lead characteristics among the 3 groups are shown in Table 2 . Lead failure occurred in 33% of Fidelis leads, 6% of Riata/Riata ST leads, and 6% of all other leads (P<0.001), and lead extraction was performed in 79%, 67%, and 81%, respectively. Fidelis leads failed at an older median lead age of 2.4 years compared with 0.7 years for all other leads. The most common failure mechanism was conductor fracture in 61% of Fidelis leads compared with 32% of all other leads ( Table 2) .
Independent predictors of lead failure were identified using multivariable analysis with Cox proportional hazard modeling ( Table 3) Fidelis leads increased the likelihood of lead failure. The presence of CHD, single-chamber ICDs, and single-coil leads did not show an independent effect on the hazard of lead failure. When Fidelis leads were excluded from the multivariable Cox proportional hazard model for independent predictors of lead failure, none of the variables showed statistical significance.
Inappropriate shocks associated with lead failure were experienced by 40% of patients (53 of 132) in 39% of the leads (54 of 139). Patient characteristics did not differ between those who did and those who did not experience lead failure-related inappropriate shocks. On the other hand, comparison of lead characteristics showed a higher incidence of conductor fracture in leads associated with inappropriate shocks (69%) compared with failed leads with no shocks (45%; P=0.014).
Lead Failure for Sprint Fidelis Leads
There were 300 Sprint Fidelis leads, which accounted for 71% of all failed leads (98 of 139) and 85% of all failed thin leads (98 of 115). For the 4 Fidelis models reported in this study (6930, 6931, 6948, and 6949), the number of failed leads was 0 of 1, 57 of 138 (41%), 3 of 16 (19%), and 38 of 145 (26%), respectively. Of the failed single-coil leads, 72% were Fidelis model 6931 (57 of 79). Fidelis leads accounted for 80% of failed leads (43 of 54) associated with inappropriate shocks; when excluded, 27% of failed leads (11 of 41) were associated with inappropriate shocks.
Lead Survival
Actuarial survival for all leads was 95%, 83%, and 71% at 1, 3, and 5 years after implantation, respectively, as shown in the Kaplan-Meier curve in Figure 2A . Eighty-two patients underwent >1 lead implantation during this study. Survival of leads initially present at the time of enrollment in this study was compared with all subsequently implanted leads on the same patients during the study period, and no significant difference was identified ( Figure 2B ). For the initial leads, actuarial survival was significantly different when Fidelis and non-Fidelis leads were compared (95%, 76%, and 62% versus 96%, 90%, and 89% at 1, 3, and 5 years, respectively; log-rank P<0.001; Figure 2C ). For non-Fidelis thin leads, the survival was 94% and 91% at 1 and 3 years.
When the 5-year actuarial failure rate was used, the average annual failure rate was 6.5% for all leads, 9.1% for Fidelis leads, and 2.3% for non-Fidelis leads. When lead survival was evaluated by age at implantation, there was an overall incremental and significant difference (log-rank P=0.002), specifically between the <8-year-old compared with the >18-year-old groups (adjusted log-rank P=0.015), with a higher failure rate in the younger age group ( Figure 2D ).
Lead Extraction
There were a total of 143 lead extractions (15%) in this study, involving 137 patients (16%). A large proportion of extracted leads, 76% (109 of 143), were failed leads, and the remaining 34 (24%) were extracted without reported failure. Extraction Table 4 and are compared between simple traction (no locking stylet or sheath) and advanced extraction (locking stylet with a sheath) techniques. In terms of lead characteristics, older lead age did correlate with the use of an advanced extraction technique (2.7±1.4 versus 1.0±0.9; P<0.001). The percentage of single and ePTFE-coated coils did not differ between the 2 extraction techniques, although only 10 ePTFEcoated leads underwent extraction, of which 6 had failed. Of the only 16 extracted Optim-coated leads, the majority (13 of 16) were removed by simple traction. On multivariable analysis, the only independent predictor of an advanced extraction was older lead age at extraction ( Table 5 ). Patient characteristics were also compared between those undergoing extractions with the use of a powered and those with a nonpowered sheath; no differences were identified. Complications were 
Discussion
The PLEASE study is, to the best of our knowledge, the largest international study on the outcome of ICD leads in pediatric and CHD patients. The lead failure prevalence was 14%, affecting 15% of patients, at an average of 2.0 years after implantation. The majority of implanted leads (77%) were either thin or ePTFE coated, and 83% of lead failure involved thin ICD leads, mostly recalled Fidelis, whereas only 5% were ePTFE-coated leads. The 5-year survival for Fidelis leads was only 62% compared with 89% for all non-Fidelis leads. A recent single-center pediatric series 5 reported on 71 ICD leads (28 Fidelis) with a 5-year survival rate of 90%, much higher than the 71% overall lead survival in our cohort. However, although 50% of their failed leads (2 of 4) were Fidelis, the overall Fidelis failure rate of only 7% (2 of 28) was probably underestimated because the study 5 This study identified independent predictors of lead failure in pediatric and CHD patients, including Fidelis leads and younger age at implantation. When analyzed separately, non-Fidelis thin leads were not found to be an independent risk factor for lead failure. Although Fidelis leads have been removed from the market, anticipatory management of implanted and still functional leads will continue to represent a challenge for both physicians and patients. The actuarial annual rate of lead failure for Fidelis leads in this study was 4-fold (9.1%/y) that of non-Fidelis leads (2.3%/y). This is significantly higher than the Fidelis failure rates of 2.8%/y 6 or 17% at 5 years (3.7%/y) 7 recently reported in 2 studies involving adult patients.
One important and modifiable clinical variable that emanates from this study is the increased risk of lead failure with younger age at implantation; a finding that supports a longstanding clinical impression. Although younger patients were more likely to be implanted with thin and single-coil leads during this study period, younger age at implantation remained an independent risk factor for lead failure after adjustment for these lead characteristics on multivariable analysis. Hence, when the clinical scenario allows it, patient age and size at implantation should continue to be essential considerations in pediatric patients being evaluated for transvenous ICD implantation. We identified an incremental risk for the <12-year-old and specifically the <8-year-old groups. For certain patients, an alternative nontransvenous system can be considered. A recent adult cohort study also identified younger age as a risk factor for Fidelis lead failure; however, the younger age identified in that study is most likely qualitatively and quantitatively different. 6 A single-chamber ICD system was not identified as a protective factor associated with lead failure. However, the use of single-rather than dual-chamber implants in this patient population is favored for several reasons, including the potential value of decreasing intravascular injury or occlusion and eventually decreasing the risk associated with lead extraction. Single-coil leads were not found to be independent predictors of lead failure after controlling for thin leads and other variables in the multivariable model. This is a favorable finding, for the use of single-coil leads has recently become a preferred trend with the hope for less complex extractions. 8 Inappropriate shocks heralded lead failure (mostly as a result of conductor fracture) in 40% of patients with failed leads or 6% of the total cohort. The inappropriate shock rate in patients with failed leads is similar to the 46% and 56% reported in recent multicenter studies on adult patients with failed Fidelis leads. 6, 9 The overall inappropriate shock rate from lead failure is lower than the previously reported 14% in a large pediatric and congenital study spanning a much longer 12-year period. 10 The proportion of failed leads that underwent extraction was similar between the Fidelis, Riata/Riata ST, and all other lead groups. Complications occurred mostly in the advanced extraction group; however, the difference was not statistically significant. The overall 4% major complication rate is in comparison to a 3% major complication rate previously reported in a similar patient population 4 and a recently reported rate of 7% in a systemic study of Fidelis lead revision in an adult patient population. 11 As previously reported, older lead age at extraction was the most important predictor of the need for an advanced extraction. 4 Coil insulation with either ePTFE or Optim was not a protective predictor on multivariable analysis in this study. The advantage of ePTFE leads during lead extraction remains to be proven in the pediatric population. 12, 13 In addition, the potential disadvantage of the integrated bipolar sensing system in young patients with small right ventricular cavities should be taken into consideration when such leads are implanted.
Limitations of this study included the relatively short follow-up period and the unavailability of clinical data on the The study was probably underpowered to detect significant predictors of lead failure when Fidelis leads were excluded. The study was also underpowered to detect a possible advantage of specific coil insulations during lead extraction or a significantly higher incidence of complications with advanced extraction.
This multicenter pediatric study highlights one of the major challenges in ICD use in young patients who experience a significantly high rate of lead and system failure. This high failure rate in this patient population, in the context of a long life expectancy of several decades, dictates the exposure to multiple device-related complications and the need for a multitude of procedures, including high-risk lead extractions. In addition, the discouraging findings in this and other studies of the high failure rate of a subset of thin leads may have indicated a lower lead diameter cutoff until better technology and lead mechanics are identified. Overall, the inherent imperfections of ICD systems necessitate the consideration of long-term strategies aimed at minimizing the clinical impact of lead failure and extraction procedures in the young. The optimistic goal of improving lead endurance, durability, and extractability still has not been adequately achieved for the youngest ICD recipients.
Conclusions
This study demonstrated that ICD leads implanted in children and CHD patients in 2005 to 2010 had suboptimal performance overall. Fidelis lead failure rate was significantly higher than that reported in adult studies. Modifiable clinical variables that may improve patient outcome include postponing transvenous implantations, when clinically possible, until an older age. Lead extraction, often requiring an advanced approach with increasing lead age, is a common eventuality for many young patients with ICDs and should be performed in qualified centers. 
